PMID- 24036520
OWN - NLM
STAT- MEDLINE
DCOM- 20160613
LR  - 20150909
IS  - 1752-8976 (Electronic)
IS  - 1470-3203 (Linking)
VI  - 16
IP  - 3
DP  - 2015 Sep
TI  - Spironolactone enhances the beneficial effect of aliskiren on cardiac structural 
      and electrical remodeling in TGR(mRen2)27 rats.
PG  - 488-94
LID - 10.1177/1470320313497818 [doi]
AB  - OBJECTIVE: To investigate the influence of simultaneous administration of 
      spironolactone (20 mg/kg per day, intraperitoneal (i.p.)) and aliskiren (50 mg/kg 
      per day, i.p.) for a period of eight weeks on cardiac remodeling in TGR(mRen2)27 
      rats. METHODS: Echocardiographic and electrophysiological and histological 
      methods were used to determine the influence of spironolactone and aliskiren on 
      cardiac remodeling. RESULTS: 1) the beneficial effect of aliskiren on SBP was 
      enhanced by simultaneous administration of spironolactone; 2) echocardiographic 
      studies showed that the left ventricle diameter (LVD), the left ventricle end 
      diastolic volume (LVEDV) and the left ventricle posterior wall thickness (LVPW) 
      were significantly reduced by the combination of both drugs when compared with 
      aliskiren alone; 3) the ejection fraction was also increased; 4) histological 
      studies indicated a greater decline in perivascular and interstitial fibrosis 
      when both drugs were used; 5) the decrease of electrical remodeling of the left 
      ventricle caused by aliskiren was further reduced by simultaneous administration 
      of spironolactone; 6) the cardiac refractoriness increased by aliskiren was 
      further incremented by spironolactone. Spironolactone (20 mg/kg per day) alone 
      increased the ejection fraction and reduced LVD, LVEDV and LVPW but its effect 
      was smaller than that achieved with the combination spironolactone plus 
      aliskiren. CONCLUSION: The combination of an aldosterone inhibitor with a direct 
      renin inhibitor proved to be of greater benefit for cardiac structural and 
      electrical remodeling in this experimental model of hypertension than aliskiren 
      alone.
CI  - (c) The Author(s) 2013.
FAU - De Mello, Walmor C
AU  - De Mello WC
AD  - School of Medicine, University of Puerto Rico, San Juan, USA 
      walmor.de-mello@upr.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130913
PL  - England
TA  - J Renin Angiotensin Aldosterone Syst
JT  - Journal of the renin-angiotensin-aldosterone system : JRAAS
JID - 100971636
RN  - 0 (Amides)
RN  - 0 (Fumarates)
RN  - 27O7W4T232 (Spironolactone)
RN  - 502FWN4Q32 (aliskiren)
RN  - EC 3.4.23.15 (Renin)
SB  - IM
MH  - Amides/administration & dosage/*pharmacology
MH  - Animals
MH  - Blood Pressure/drug effects
MH  - Coronary Vessels/drug effects/pathology
MH  - Echocardiography
MH  - Fibrosis
MH  - Fumarates/administration & dosage/*pharmacology
MH  - Heart/*anatomy & histology/drug effects
MH  - Heart Conduction System/drug effects
MH  - Injections, Intraperitoneal
MH  - Male
MH  - Rats, Transgenic
MH  - Renin/*genetics
MH  - Rest
MH  - Spironolactone/administration & dosage/*pharmacology
MH  - Systole/drug effects
MH  - Ventricular Remodeling/*drug effects
OTO - NOTNLM
OT  - TGR(mRen2)27 rat
OT  - aliskiren
OT  - cardiac
OT  - remodeling
OT  - spironolactone
EDAT- 2013/09/17 06:00
MHDA- 2016/06/14 06:00
CRDT- 2013/09/17 06:00
PHST- 2013/02/14 00:00 [received]
PHST- 2013/04/22 00:00 [accepted]
PHST- 2013/09/17 06:00 [entrez]
PHST- 2013/09/17 06:00 [pubmed]
PHST- 2016/06/14 06:00 [medline]
AID - 1470320313497818 [pii]
AID - 10.1177/1470320313497818 [doi]
PST - ppublish
SO  - J Renin Angiotensin Aldosterone Syst. 2015 Sep;16(3):488-94. doi: 
      10.1177/1470320313497818. Epub 2013 Sep 13.